Lv5
830 积分 2024-08-23 加入
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial
1个月前
已完结
我国城镇掌跖脓疱病的流行病学特征和经济负担分析
1个月前
已完结
Risks of Comorbidities in Patients With Palmoplantar Pustulosis vs Patients With Psoriasis Vulgaris or Pompholyx in Korea
1个月前
已完结
Outcomes in Patients with Psoriasis Following Apremilast Treatment: Results from the German Psoriasis Registry PsoBest
2个月前
已关闭
Efficacy and Safety of Apremilast for the Treatment of Japanese Patients With Palmoplantar Pustulosis: 52-week Results From a Phase 3, Randomized, Placebo-controlled Study
2个月前
已关闭
Real-world long-term drug survival of dupilumab in palmoplantar pustulosis: A 3-year observational follow-up
4个月前
已完结
Upadacitinib Versus Acitretin for the Resolution of Pustules in Palmoplantar Pustulosis During Acute Phase: A Single-Center, Open-Label Prospective Cohort Study
4个月前
已完结
Associations between HLA-Cw1 and Systemic Treatment Response of Asian Psoriasis Patients HLA-Cw1
6个月前
已完结
Safety assessment of apremilast: real-world adverse event analysis from the FAERS database
7个月前
已完结
皖公网安备34019202002308
